Product Name: RSK2-PCT
Product Number: AB-NK165-3
Size: 25 µg      Price:89.00
      $US
Target Full Name: Ribosomal S6 protein-serine kinase 2; Ribosomal protein S6 kinase alpha-3

Target Alias: 90 kDa ribosomal protein S6 kinase 3; CLS; HU-3; Insulin-stimulated protein kinase 1; ISPK1; ISPK-1; KS6A3; MAPKAPK1B; MRX19; pp90RSK2; RP11-393H10_3; RPS6KA3; S6K-alpha 3

Product Type Specific: Protein kinase pan-specific antibody

Antibody Code: NK165-3

Antibody Target Type: Pan-specific

Protein UniProt: P51812

Protein SigNET: P51812

Antibody Type: Polyclonal

Antibody Host Species: Rabbit

Antibody Immunogen Source: Human RSK2 (RPS6KA3) sequence peptide Cat. No.: PE-01AQN85

Antibody Immunogen Sequence: CNRNQSPVLEPVGRS

Antibody Immunogen Description: Corresponds to amino acid residues N711 to S724; Pre-C-terminus

Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.

Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.

Antibody Concentration: 0.5 mg/ml

Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol

Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.

Product Use: Western blotting | Antibody microarray

Antibody Dilution Recommended: 2 µg/ml for immunoblotting

Antibody Potency: Very strong immunoreactivity of a target-sized protein by Western blotting in mouse brain.

Antibody Species Reactivity: Human

Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 80-85 kDa.

Antibody Specificity: Medium-High
Antibody Cross Reactivity: Some strong cross-reactive proteins (~39 kDa and ~24 kDa) in mouse brain and (~50 kDa and ~45 kDa) in muscle, and (~24 kDa) in testes.

Related Product 1: RSK2-PCT blocking peptide

Related Product 2: RSK2-BKCD pan-specific antibody (Cat. No.: AB-NK165-2)

Related Product 3: RSKSubtide - RSK1_d1 (RPS6KA2) protein kinase substrate peptide

Related Product 4: RPS6 (230-238) KinSub - 40S ribosomal protein S6 (K230-R238, human) peptide; p70S6K protein kinase substrate peptide

Related Product 5: RPS6 (230-239) KinSub - 40S ribosomal protein S6 (K230-A239, human) peptide; RSK protein kinase substrate peptide

Scientific Background: RSK2 (RPSKA3) is one of several protein kinases that can phosphorylate KinSub1RRDSV. RSK2 is a protein-serine/threonine kinase of the AGC group and RSK family, and is a member of the RSK (ribosomal S6 kinase) family of growth factor-regulated kinases. It is moderate to highly expressed in most tested human tissues. RSK proteins have two kinase catalytic domains and are phosphorylated by MAPK proteins in response to growth factors, polypeptide hormones, and neurotransmitters. RSKs function in the regulation of cell cycle progression, cell differentiation, and cell survival. RSK2 is necessary for epidermal growth factor (EGF)-mediated phosphorylation of histone H3, a key step in the mitogenic response of mammalian cells. RSK2 is activated by phosphorylation at S227, S369 and T577. Phosphorylation at Y529 induces interaction with ERK1and ERK2, as well as FGFR3. RSK2 forms a complex with either ERK1 or ERK2 in quiescent cells. RSK2 has been shown to mediate growth factor signalling via Ras and MAPK leading to the induction of CREB S133 phosphorylation and activation. Mutations in RSK2 have been shown to be responsible for Coffin-Lowry syndrome (CLS) which is a X-linked disorder characterized by severe psychomotor retardation, facial and digital dysmorphisms, and progressive skeletal deformations. RSK2 has also been linked with the development of breast carcinomas, gastric adenocarcinomas, and glioblastoma multiforme (GM). Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.
Figure 1. Dot blotting RSK2-PCT antibody with recombinant purified proteins.